Recommendation for Postoperative Radiotherapy Dose in Malignant Melanoma
For postoperative adjuvant radiotherapy in malignant melanoma, use 48 Gy in 20 fractions over 4 weeks as the standard regimen.
Evidence-Based Rationale
The 48 Gy/20 fraction schedule is supported by the only prospective randomized phase III trial in this setting 1. This landmark trial of 250 patients with high-risk nodal disease demonstrated that 48 Gy in 20 fractions significantly reduced lymph node field recurrence (HR 0.54,95% CI 0.33-0.89, P=0.021) after a mean follow-up of 73 months 1. This represents Level I evidence from a prospective randomized controlled trial—the highest quality data available for this specific question.
Why Not 60 Gy in 30 Fractions?
The 60 Gy/30 fraction regimen lacks prospective validation in melanoma. While retrospective data suggest doses of at least 50 Gy may improve regional control 1, these studies are subject to selection bias and do not establish superiority of higher total doses. The NCCN guidelines explicitly reference the 48 Gy/20 fraction schedule from the phase III trial as the evidence-based standard 1.
Supporting Evidence for Hypofractionation
Multiple lines of evidence support that hypofractionated regimens are equally effective:
Retrospective comparative data: A 2023 study of 335 patients showed equivalent 5-year lymph node field control between hypofractionated (median 33 Gy/6 fractions) and conventional fractionation (median 48 Gy/20 fractions): 86.0% vs 85.5%, P=0.87 2. No differences in recurrence-free survival or overall survival were observed.
Guideline consensus: NCCN guidelines state that "hypofractionated radiotherapy appears to be equally effective as standard fractionation" based on multiple retrospective studies 1.
Acceptable toxicity profile: The phase III trial using 48 Gy/20 fractions reported frequent grade 2-4 toxicities (primarily skin/subcutaneous tissue, pain, nerve damage, joint events) 1, but a prospective phase II study confirmed this regimen had acceptable late toxicity 3.
Clinical Algorithm
Use 48 Gy in 20 fractions (2.4 Gy per fraction) over 4 weeks when:
- Patient has high-risk nodal disease after lymphadenectomy
- ≥1 parotid, ≥2 cervical/axillary, or ≥3 groin positive nodes
- Maximum nodal diameter ≥3 cm (neck) or ≥4 cm (axilla/groin)
- Extranodal extension present
Important Caveats
Treatment-related morbidity: The phase III trial showed significantly increased 5-year treatment-related morbidity with radiotherapy (20% vs 13%, P=0.004), particularly lymphedema 1. Counsel patients accordingly.
No survival benefit demonstrated: While the 48 Gy/20 fraction regimen improved regional control, it did not show statistically significant improvements in relapse-free survival or overall survival 1. The primary benefit is local/regional disease control.
Technical considerations: When treating operative scars, use bolus to reduce dermal recurrence risk 4. One study found 4 of 5 recurrences in radiated patients were dermal, with 3 occurring where no bolus was used over the operative scar.
Dose considerations: Retrospective data suggest cumulative equivalent dose (eqTD2) <60 Gy and conventional fractionation (≤2.5 Gy per fraction) are recommended 4. The 48 Gy/20 fraction schedule (2.4 Gy per fraction) meets these criteria.